I期子宫内膜癌盆腔淋巴清扫术的意义

目的：探讨I期子宫内膜癌患者预后的相关因素及盆腔淋巴清扫术对其预后可能的影响。方法：收集1997年8月至2005年3月浙江大学医学院附属妇产科医院临床I期子宫内膜癌患者202例，分析影响预后的各项临床病理指标，寿命表法计算生存率，比较盆腔淋巴清扫组与平行淋巴结清扫组的复发率，并发症。结果：I期子宫内膜癌盆腔淋巴转移率1．53％。病理类型、腹腔细胞学、盆腔淋巴转移、手术-病理分期、肌层浸润及CA125，值是影响预后的独立因素。I期低危患者，盆腔淋巴清扫术无助于提高生存率（P〉0．05），其复发率也无明显差异（P〉0．05），手术并发症率明显增高（P〈0．05）；I期高危患者，盆腔淋巴清扫术未能延长其生存期（P〉0．05），但可减少复发的例数。并发症率无明显增多（P〉0．05）。结论：特殊病理类型，腹腔细胞学阳性，手术-病理分期高，盆腔淋巴转移，深肌层浸润及CA125〉100U／ml的患者预后较差（P〈0．05）。I期高危子宫内膜癌患者盆腔淋巴清扫术具有一定的临床意义。     

淋巴结阳性率在ⅠB～ⅡA期宫颈癌患者中的临床意义

目的:研究淋巴结阳性比率(LNR)对IB~IIA期宫颈癌患者无进展生存期(PFS)及总生存期(OS)的影响。方法:回顾分析2010年1月~2015年12月我院收治的102例经根治性子宫切除±双侧卵巢切除+盆腔淋巴结清扫±腹主动脉淋巴结清扫术的淋巴结转移阳性的102例IB~IIA期宫颈癌患者的临床资料。采用单因素和多因素分析LNR、分期、病理类型、组织学分级、肿瘤大小、辅助治疗对PFS及OS的影响。结果:单因素分析显示,LNR、分期对PFS、OS有显著影响。多因素分析显示,LNR10%的患者PFS更差(HR=0.151,P=0.047,95%CI为0.023~0.974);而LNR10%患者的OS与LNR≤10%者比较,差异无统计学意义。结论:LNR可以作为判断IB~IIA期宫颈癌患者PFS的一项独立危险因素。     

子宫癌肉瘤41例临床病理分析

目的:探讨癌肉瘤的临床病理特征对预后的影响。方法:回顾分析2000年1月至2011年6月复旦大学附属妇产科医院收治的41例子宫癌肉瘤患者的临床病理特征,采用Kaplan-Meier生存分析和Cox回归多因素分析评价各因素对预后的影响,并比较肿瘤上皮成分及间叶成分与预后的关系。结果:患者的3年总生存率为57.5%,3年无瘤生存率为52.5%。单因素分析提示,FIGO分期(2009年)Ⅲ~Ⅳ期、深肌层浸润、宫颈间质侵犯、淋巴结转移与预后密切相关。Cox回归多因素分析提示,淋巴结转移(P=0.042,OR=3.375,95%CI为1.045~10.897)是影响预后的独立因素。肿瘤的上皮成分和间叶成分中p53表达无明显差异,上皮成分为非内膜样腺癌的总生存率低于内膜样腺癌(P=0.074);但不同的间叶成分预后无明显差异。结论:手术病理分期为晚期、病理提示深肌层浸润、宫颈间质侵犯、淋巴结转移等提示预后差;而淋巴结转移是影响预后的独立因素。癌肉瘤上皮成分和间叶成分可能为单克隆来源;上皮成分为影响肿瘤生物学行为的主导成分。     

226例晚期子宫内膜癌的临床病理特征及治疗与其预后的相关因素分析

目的:分析晚期子宫内膜癌患者的临床病理特征、治疗情况及生存资料,探讨影响患者预后的独立因素。方法:收集并分析四川大学华西第二医院手术并经术后病理组织学证实为FIGOⅢ期及Ⅳ期子宫内膜癌患者226例的临床病理及生存资料,采用多因素Cox回归分析晚期子宫内膜癌预后[无进展生存(PFS)、总体生存(OS)]的相关因素。结果:中位OS时间为76月(95%CI 61.5~90.5),中位PFS时间为68月(95%CI 55.4~80.6)。多因素分析结果显示,年龄≥54岁、低分化、非子宫内膜样癌、有淋巴脉管浸润、腹主动脉旁淋巴结转移阳性、腹水细胞学阳性、术后残留癌灶直径1 cm是影响PFS及(或)OS的独立危险因素(P0.05),而术后行不同的辅助治疗是PFS及(或)OS的保护因素(P0.05)。结论:对于具有晚期子宫内膜癌预后的独立危险因素的患者,因其预后较差,术后放化疗有助于提高其生存率,应重视术后辅助治疗与随访监测。     

子宫肉瘤诊治及预后的相关因素

子宫肉瘤是一类临床少见的恶性肿瘤,由于缺乏特异性临床表现,因此术前诊断率极低。子宫肉瘤病理分类较复杂,主要包括平滑肌肉瘤、癌肉瘤、子宫内膜间质肉瘤与未分类肉瘤等。近年来,关于子宫肉瘤病理学特征、临床病理分期、治疗与预后因素等方面的研究均取得了很大进展。     

子宫肉瘤诊治及预后的相关因素

子宫肉瘤是一类临床少见的恶性肿瘤,由于缺乏特异性临床表现,因此术前诊断率极低。子宫肉瘤病理分类较复杂,主要包括平滑肌肉瘤、癌肉瘤、子宫内膜间质肉瘤与未分类肉瘤等。近年来,关于子宫肉瘤病理学特征、临床病理分期、治疗与预后因素等方面的研究均取得了很大进展。     

子宫颈高级别神经内分泌癌术后化疗周期的临床分析

目的：评估子宫颈高级别神经内分泌癌（HGNECC）术后不同化疗周期对患者3年的无疾病进展生存期（PFS）和总生存期（OS）的影响。方法：收集2015年10月至2020年12月接受手术及术后辅助化疗的HGNECC患者共303例,按照术后辅助化疗周期（4～6个）分为3组：4周期组134例、5周期组11例和6周期组158例。比较3组基线资料差异及化疗周期对3年PFS和OS的影响,分析不同临床及病理因素对患者预后的影响。应用Log-rank检验进行单因素分析及Kaplan-Meier法估计生存曲线,Cox风险评估模型进行多因素生存分析,多角度分析探索影响HGNECC患者局部无复发生存和远处转移生存的相关临床因素。结果：(1)单因素分析提示3年PFS与肿瘤分期、颈体交界是否阳性、中高危因素个数、化疗周期有关,3年OS与肿瘤分期有关,差异均有统计学意义（P <0.05）;(2)肿瘤分期为ⅠB1期、颈体交界阴性、中高危因素个数为2、化疗6周期患者的3年PFS较长（P <0.05）,其他因素对3年PFS无显著影响（P> 0.05）;(3)肿瘤分期较早的患者3年OS较长（P <0.05）,其他因素对早期HGNECC患者的3年OS无显著影响;(4)多因素Cox回归分析提示,颈体交界阳性的患者（HR4.066,95%CI 1.606～10.291）、化疗周期为5周期的患者（HR4.726,95%CI 1.628～13.719）癌症复发或者死亡的危险性增加（P <0.05）。结论：对于根治性术后的HGNECC患者,术后化疗周期的增加可能对短期内的PFS有益,而对OS无明显影响。     

子宫内膜浆液性乳头状癌33例临床分析

目的 分析子宫内膜浆液性乳头状癌的临床病理特点,探讨其治疗及预后.方法 回顾性分析1996年1月-2005年12月在复旦大学附属肿瘤医院手术治疗的33例子宫内膜浆液性乳头状癌患者的临床病理资料.结果 33例患者中,手术病理分期Ⅰ期11例,Ⅱ期2例,Ⅲ期7例,Ⅳ期13例.早期患者（Ⅰ期和Ⅱ期）13例,占39%;晚期患者（Ⅲ期和Ⅳ期）20例,占61%.Ⅰ、Ⅲ、Ⅳ期患者的3年总生存率分别为77.4%、53.3%、12.1%,3者间比较,差异有统计学意义（P=0.008）.对手术病理分期、淋巴结受累、肌层浸润深度、病理分级、脉管浸润和p53基因表达情况与预后的关系进行统计学分析,单因素分析发现,仅手术病理分期（P=0.008）和肌层浸润深度（P=0.025）与预后有关;多因素分析发现,仅手术病理分期和病理分级与预后有关（P均＜0.05）.晚期患者中,行术后辅助化疗者的生存时间平均为30个月,明显长于未化疗者的6个月（P=0.014）.结论 子宫内膜浆液性乳头状癌确诊时多为晚期,预后差.治疗强调全面的手术分期,术后辅助化疗可改善患者的预后.     

子宫腺肉瘤的研究进展

腺肉瘤是由良性腺上皮和恶性间质构成的一种低度恶性的混合性肿瘤,大多数腺肉瘤原发于子宫内膜,偶可发生在卵巢或子宫外组织。子宫腺肉瘤是罕见的女性生殖道恶性肿瘤,以绝经后妇女多见,缺乏特异的临床症状,多数患者表现为阴道出血、宫颈口脱出物及子宫增大。该病早期诊断困难,超声、磁共振成像（MRI）等影像学检查有一定的诊断价值,“袖口”状结构是术后病理检查的特征性表现。子宫腺肉瘤的发生可能与子宫内膜异位症、长期雌激素暴露等因素有关,但其具体的发病机制目前尚未明确。该病的主要治疗方法为全子宫双附件切除（因淋巴结转移少见故不常规行淋巴结清扫）,放化疗及激素治疗疗效尚不确切。但患者的生存时间及肿瘤的术后复发与是否伴肉瘤过度生长、疾病分期、子宫肌层侵犯深度、有无淋巴结转移及脉管浸润等因素密切相关。     

Ⅰ～Ⅲ期子宫内膜癌淋巴结转移及预后的相关因素分析

目的:探讨国际妇产科联盟(FIGO)Ⅰ～Ⅲ期子宫内膜癌患者的临床病理特征与淋巴结转移及预后的相关因素。方法:选择2009～2020年于安徽医科大学第一附属医院妇科因子宫内膜癌行分期手术的患者1346例为研究对象(其中130例淋巴结阳性),对其临床病理特征行单因素及Logistic、Cox多因素回归模型分析与淋巴结转移及生存期预后的相关因素。结果:(1)单因素分析提示:病理类型、组织学分级、肌层浸润深度、肿瘤直径、子宫颈侵犯、淋巴脉管间隙浸润(LVSI)、术前CA_(125)及卵巢受累与淋巴结转移有关(P0.05)。多因素的Logistic回归分析显示:病理类型为非子宫内膜样癌、子宫颈侵犯、LVSI阳性、术前CA_(125)≥35 U/L、卵巢受累是淋巴结转移的独立危险因素(OR1,P0.05)。(2)单因素分析提示:病理类型、组织学分级、肌层浸润深度、子宫颈侵犯、LVSI、淋巴结转移、卵巢受累及术后辅助治疗与总生存期有关(P0.05)。多因素Cox回归验证及Kaplan-Meier生存曲线显示:非子宫内膜样癌、子宫颈侵犯、LVSI阳性和淋巴结转移是影响总生存期的独立危险因素(HR1,P0.05)。结论:特殊病理类型、子宫颈侵犯、LVSI阳性、术前CA_(125)≥35 U/ml及卵巢受累,对淋巴结转移风险具有独立预测意义。特殊病理类型、子宫颈侵犯、LVSI阳性及淋巴结转移是临床预后不良的有力预测因子。进一步完善子宫内膜癌分期手术和术后病理,为指导患者个体化治疗提供有效帮助。     

Uterine adenosarcoma with sarcomatous overgrowth versus uterine carcinosarcoma: comparison of treatment and survival

OBJECTIVE: Uterine adenosarcoma with sarcomatous overgrowth (ASSO) is a rare variant of uterine sarcoma first described in 1989. This clinicopathologic study was undertaken to compare the treatment and survival of uterine adenosarcoma with sarcomatous overgrowth to that of uterine carcinosarcomas. METHODS: A review of uterine sarcomas diagnosed at Washington Hospital Center from January 1988 to December 1998 was performed. Records were reviewed for demographic data, surgical staging, primary and adjuvant therapy, metastatic site, disease recurrence, and survival. All pathology was reviewed and diagnosis confirmed. Statistical analysis included chi(2) test and Student's t test. Kaplan-Meier survival curves were plotted to estimate the median and 5-year survival times. The log-rank test was used to compare survival times. A P value <0.05 was considered significant. RESULTS: Sixty patients were diagnosed with uterine sarcoma at Washington Hospital Center. Of these, 33 (55%) were uterine carcinosarcomas, 11 (18%) ASSOs, 6 (10%) adenosarcomas, and 10 (17%) leiomyosarcomas. Of the patients diagnosed with uterine ASSO, 3 (27%) were stage I, 3 (27%) stage II, 1 (9%) stage III, and 4 (36%) stage IV. All 11 patients with uterine ASSO underwent total abdominal hysterectomy with bilateral salpingo-oophorectomy and tumor debulking. Postoperative adjuvant therapy included chemotherapy (n = 4), radiation (n = 4), combination radiation and chemotherapy (n = 1), and no adjuvant therapy (n = 2). The overall median survival time of patients with uterine ASSO was 13 months. Nine of eleven patients are dead of disease, and two patients (both with stage I) are alive without evidence of disease at 18 and 19 months. Thirty-three patients with carcinosarcoma were identified, with follow-up available on 29 patients. Of these, 10 (34%) were stage I, 6 (22%) stage II, 3 (10%) stage III, and 10 (34%) stage IV. Twenty-seven of the twenty-nine patients diagnosed with carcinosarcoma underwent surgical therapy to include total abdominal hysterectomy, bilateral salpingo-oophorectomy, staging and tumor debulking. Two patients died prior to treatment. Postoperative adjuvant therapy included chemotherapy (n = 9), radiation (n = 13), combination (n = 1), and no further therapy (n = 4). Twenty of the twenty-nine patients are dead of disease; there were nine surviving patients at the time of this report (stage I-5, stage II-3, stage III-1). The median survival of these patients was 31 months, with an overall 5-year survival of 22%. Comparison of the Kaplan-Meier survival curves using the log-rank test suggests a worse prognosis for uterine ASSO. However, this did not reach statistical significance (P = 0.0522). CONCLUSIONS: Patients diagnosed with uterine ASSO have a poor prognosis similar to that of carcinosarcoma. Management should include complete surgical staging. Additional therapy in the form of radiation, chemotherapy, or both has been reported; however, the superiority of one modality could not be determined from our data.     

Adjuvant Treatment Modalities,Prognostic Factors,and Outcome of the Uterine Carcinosarcoma

ObjectiveTo determine the impact of adjuvant therapy and other factors associated with the recurrence and survival of patients with uterine carcinosarcoma (UCS).MethodsA total of 102 patients who underwhent surgery for UCS from 1998 to 2017 were included in the analysis. Data were analyzed using Kaplan–Meier methods and Cox proportional hazards regression.ResultsAt 240 months, the actuarial recurrence rate was 34.3%. Distant recurrence was the most common recurrence pattern. Patients with higher CA 125 levels, sarcoma dominance, cervical involvement, advanced stage, no lymphadenectomy, and residual tumour had a significiantly higher risk of recurrence. Five-year disease-free survival (DFS) and overall survival (OS) were 67% and 77%, respectively. FIGO stage was found to be an independent prognostic factor for DFS and OS. Sarcoma dominance was independently associated with decreased OS.ConclusionSarcoma dominance is associated with poor survival in UCS. Adjuvant treatment was not found to affect recurrence or survival. Given this finding, more effective postoperative strategies are needed.     

The prognostic relevance of histological type in uterine sarcomas: a Cooperation Task Force (CTF) multivariate analysis of 249 cases

PURPOSE OF INVESTIGATION: The objective of this retrospective multicenter study was to assess the prognostic relevance of histologic type in uterine sarcomas. METHODS: The hospital reports of 249 patients with uterine sarcomas were reviewed. Surgery was the initial therapy for all patients. Histologic type was leiomyosarcoma in 95 cases, low-grade endometrial stromal sarcoma (ESS) in 19, high-grade ESS in 34, and carcinosarcoma in 101. Postoperative treatment was given without well-defined protocols. Median follow-up of survivors was 97 months. RESULTS: In the whole series 2-year, 5-year, and 10-year survival rates were 53.5%, 41.6%, and 35.8%, respectively, and median survival was 31 months. At univariate analysis survival was significantly related to stage (p = 0.0001), mitotic count (p = 0.0001), and histologic type (low-grade ESS vs leiomyosarcoma vs carcinosarcoma vs high-grade ESS, median: not reached vs 27 months vs 21 months vs 16.5 months, p = 0.0011), but not to postoperative therapy and patient age. The Cox model revealed that tumor stage, mitotic count and histologic type were independent prognostic variables for survival. In detail, the risk of death was significantly lower for low-grade ESS (risk ratio [RR] = 0.257; 95% confidence interval [CI] = 0.071-0.931) and carcinosarcoma (RR = 0.509; 955 CI = 0.324-0.799) when compared to leiomyosarcoma. Conversely, no significant difference in survival was found between leiomyosarcoma and high-grade ESS. CONCLUSIONS: Histologic type is an independent prognostic variable for survival in uterine sarcomas. Low-grade ESS has the best clinical outcome, whereas leiomyosarcoma has the poorest one. It is noteworthy that, when adjusting for stage and mitotic count, leiomyosarcoma has a significantly worse prognosis than carcinosarcoma.     

The effect of adjuvant chemotherapy versus whole abdominopelvic radiation on the survival of patients with advanced stage uterine papillary serous carcinoma

OBJECTIVES: To compare the outcomes of stage III and IV uterine papillary serous carcinoma (UPSC) patients treated with platinum-based chemotherapy (PC) versus whole abdominopelvic irradiation (WAPI) after optimal cytoreductive surgery. METHODS: Surgically staged patients with advanced stage UPSC diagnosed between 1981 and 2002 were identified from tumor registry databases at four hospitals. Survival analyses and predictors of outcome were analyzed using Kaplan-Meier methods. RESULTS: Of the 40 patients with advanced UPSC (median age: 64.5), 84% were Caucasian, 8% were African American, and 8% were Asian. The majority of patients (85%) presented with vaginal bleeding. Twenty-seven had stage III and 13 had stage IV disease. All patients were optimally debulked; 21 patients received adjuvant PC while 19 underwent WAPI. The median follow-up was 27 months (range: 5-209). The 3-year overall survival (OS) and progression-free survival (PFS) for the patients with stage III disease were 49% and 37% compared to 37% and 31% in those with stage IV disease (P = 0.23 for OS; P = 0.41 for PFS). Women who received PC had a 3-year OS and PFS of 43% and 31% compared to 45% and 41% in those receiving WAPI, respectively (P = 0.40 for OS; P = 0.84 for PFS). CONCLUSION: Platinum-based chemotherapy or whole abdominopelvic irradiation resulted in similar survival in this series of women with optimally cytoreduced UPSC. Given the overall poor prognosis of these patients, new treatment modalities are warranted.     

Uterine adenosarcoma: An analysis on management,outcomes, and risk factors for recurrence

ObjectivesUterine adenosarcoma is a rare malignancy with little data on optimal management. We aimed to clarify the impact of adjuvant therapy in patients with uterine adenosarcoma and identify risk factors for recurrence and death.MethodsWe performed a retrospective review of patients undergoing primary evaluation and treatment for uterine adenosarcoma at a single institution from July 1982 through December 2011. Univariate and multivariate analyses were used to identify prognostic factors for progression-free survival (PFS) and overall survival (OS).ResultsWe identified 100 patients with uterine adenosarcoma, and 74 patients met the inclusion criteria. On multivariate analysis, sarcomatous overgrowth (SO) and lymphovascular space invasion (LVSI) were predictors of worse PFS and OS. Median PFS and OS were 29.4 and 55.4 months for patients with SO, compared to 105.9 and 112.4 months for patients without SO (PFS HR 2.58, 95% CI 1.37–4.84, p = 0.003; OS HR 2.45, 95% CI 1.26–4.76, p = 0.008). Among patients with stage I disease, 17 of 22 patients (77%) with SO and 8 of 37 patients (22%) without SO had a recurrence (p < 0.001). Among patients with stage I disease with SO, adjuvant therapy appeared to be associated with longer PFS and OS, but these differences were not statistically significant (PFS, 46.7 vs. 29.4 months, p = 0.28; OS, 97.3 vs. 55.4 months, p = 0.18).ConclusionIn patients with uterine adenosarcoma, the presence of SO or LVSI confers a higher risk of recurrence. We did not identify an optimal treatment strategy for patients with SO, but adjuvant therapy may be associated with prolonged PFS.     

Black race independently predicts worse survival in uterine carcinosarcoma

Objective

GOG 150 suggested that Black women had worse survival compared to White women with uterine carcinosarcoma. Our objective was to compare treatment and survival outcomes between Black and White women at a National Comprehensive Cancer Network (NCCN) cancer center serving a diverse racial population.

Methods

An IRB approved retrospective cohort study of uterine carcinosarcoma patients diagnosed between 2000 and 2012 was performed. Survival was compared by race and stratified by stage. Median progression free and overall survival (PFS and OS) were calculated using Kaplan–Meier estimates and compared with the log-rank test. Multivariate survival analysis was performed with Cox proportional hazards model.

Results

158 women were included: 93 (59%) were Black and 65 (41%) were White. 95 (60%) had early stage disease and 63 (40%) had advanced stage disease. Black women had a shorter PFS (7.9 vs. 14.2 months, p < 0.001) and OS (13.4 vs. 30.8 months, p < 0.001). There was no difference in survival between Black and White women with advanced stage disease (OS 8.5 vs. 11.8, p = 0.18). However, PFS and OS were worse in Black women compared to White women with early stage disease (PFS 13.6 vs. 77.4, p = 0.001), (OS 25.4 vs. 94.7, p = 0.003). On multivariate analysis accounting for age, stage, BMI, and adjuvant treatment, Black race remained independently associated with risk of death (HR 2.0; 95% CI 1.25–3.23).

Conclusions

Black women with uterine carcinosarcoma have worse survival compared to White women despite similar patient and treatment characteristics. This difference is largely due to differences in survival in early stage disease.     

子宫肉瘤治疗新进展

子宫肉瘤是一种少见的子宫恶性肿瘤,恶性程度高,易局部复发及远处转移,预后不佳。手术为主要的治疗方法,强调术后治疗的规范化及个体化。术后放射治疗并不能改善子宫平滑肌肉瘤患者的无瘤生存率和整体生存率,辅助性化疗因能提高子宫癌肉瘤患者的整体生存率而成为标准治疗方案。曲贝替定用于治疗晚期子宫平滑肌肉瘤有效且安全。靶向药物治疗子宫肉瘤仍处于研究探索阶段。     

Uterine sarcomas: clinical and histopathological aspects. Report on 15 cases

OBJECTIVE: Sarcoma of the uterus are rare uterine cancers with poor prognosis. They are characterised by pathological diversity and their symptomatology is not specific. The aim of this study was to review our experience with uterine sarcomas, to analyze their clinical and histopathological features, to discuss about diagnostic and therapeutic difficulties associated with these tumours and to compare our findings with previously published data. PATIENTS AND METHODS: A retrospective review, from 1996 to 2005, of cases of uterine sarcomas diagnosed and treated at the department of obstetrics-gynaecology, Belfort Hospital. Clinical and pathological features, types of treatment, tumoral stage according to the FIGO histological classification and patients' outcome were recorded. RESULTS: From 1996 to 2005, 15 cases of uterine sarcomas have been diagnosed in our department. Our study included six histological types: carcinosarcoma (n=5), leiomyosarcoma (n=3), rhabdomyosarcoma (n=2), adenosarcoma (n=2), stromal sarcoma (n=2), and undifferentiated sarcoma (n=1). Patients' mean age at the time of diagnosis was 67.6 years (range: 48-91 years). Vaginal bleeding was the most common presenting symptom, being present in 10 patients (67%). The mean time from onset of symptomatology and pathological diagnosis of sarcoma was 17.1 weeks (range: one to 60 weeks). In 10 patients (67%), definitive diagnosis of sarcoma was achieved only after surgical specimen analysis and in only three of them (30%), physical examination combined with pelvic ultrasonography had suspected malignancy. Dilation and curettage was performed in nine patients and failed to rule out neoplasia in three cases (33.5%). Fourteen patients (93%) underwent surgery: total hysterectomy with bilateral salpingo-oophorectomy in all of them and pelvic lymphadenectomy in four of them. Eight patients were in FIGO stage I, one patient in stage II, three patients in stage III and two patients in stage IV. Six patients benefited from adjuvant treatment: external beam radiotherapy and brachytherapy in three cases, brachytherapy in one case and chemotherapy in two cases. At the time of analysis, four patients were lost to follow-up, four patients were dead and with an average follow-up of 25 months, seven patients had a favourable outcome. DISCUSSION AND CONCLUSION: Uterine sarcomas are rare cancers with poor prognosis. Their symptomatology is non-specific and they are characterized by histopathological diversity. Early diagnosis is essential because patients' survival is correlated to tumour stage. However, preoperative diagnosis is often difficult and definitive diagnosis is frequently achieved after pathological analysis of hysterectomies specimens.